finance.yahoo.com
Positivefinance.yahoo.com ·
milestone pharmaceuticals q1 earnings call 180923258
WB_1305_HEALTH_SERVICES_DELIVERYWB_2156_CONTINUUM_OF_CAREWB_621_HEALTH_NUTRITION_AND_POPULATIONWB_1307_PRIMARY_CARE
Topic context
This topic has been covered 382458 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedMilestone Pharmaceuticals begins commercial sales of CARDEMYST for PSVT, with early prescription growth and formulary access. Revenue generation is nascent; cash runway supports operations. No direct impact on broader sector or supply chain. Commercial mechanism is weak and company-specific.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- CARDEMYST FDA approval on December 12, 2025
- ~600 prescriptions written by end of April 2026
- Added to Express Scripts commercial formularies covering ~25% of commercially insured patients
- Phase 3 ReVeRA-301 trial in atrial fibrillation initiated
- Cash ~$184 million, funding into H2 2027
